Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy?

International Journal of Urology

Volumn 12, Issue 8, 2005, Pages 739-744

  Miyake, Hideaki ^a   Sakai, Iori ^a   Harada, Ken Ichi ^a   Hara, Isao ^b   Eto, Hiroshi ^a  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Lymphadenectomy; Prostate cancer; Radical prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; JAPAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

BIOPSY; HUMANS; JAPAN; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 28544444724     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01122.x     Document Type: Article

References (24)

1. Han M, Partin AW, Pound CR et al. Long-term biochemical disease-free and cancer specific survival following anatomical radical retropubic prostatectomy: the 15-year Johns Hopkins experience. Urol. Clin. North Am. 2001; 28: 555-65.
2. Arai Y, Egawa S, Tobisu K et al. Radical retropubic prostatectomy: time trends, morbidity and mortality in Japan. BJU Int. 2000; 85: 287-94.
3. Miyake H, Sakai I, Harada K, Eto H, Hara I. Clinicopathological outcome of radical retropubic prostatectomy for 200 men with prostate cancer in a single institution in Japan. Acta Urol. Jpn. 2004; 50: 151-6.
4. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 2004; 63: 528-31.
5. Heidenreich A, Varga Z, von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J. Urol. 2002; 167: 1681-6.
6. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J. Urol. 2002; 168: 514-18.
7. Bader P, Burkhard FC, Markwalder R, Studer UE. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J. Urol. 2003; 169: 849-54.
8. Cheng E, Zincke H, Blute ME, Bergstralh EJ, Scherer B, Bostwick DG. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 66-73.
9. Zwergel U, Lehmann J, Wullich B et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J. Urol. 2004; 171: 1128-31.
10. McLaughlin AP, Saltzstein SL, McCullough DL, Gittes RF. Prostatic carcinoma: incidence and location of unsuspected lymphatic metastases. J. Urol. 1976; 115: 89-94.
11. Miyake H, Sakai I, Ishimura T, Hara I, Eto H. Significance of cancer detection in the anterior lateral horn on systematic prostate biopsy: the effects on pathological findings of radical prostatectomy specimens. BJU Int. 2004; 93: 57-9.
12. International Union Against Cancer. TNM Classification of Malignant Tumors, 5th edn. John Wiley & Sons, New York, 1997; 170-73.
13. Grossklaus DJ, Coffey CS, Shappell SB, Jack GS, Chang SS, Cookson MS. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J. Urol. 2002; 167: 2032-5.
14. Clark T, Parekh DJ, Cookson MS et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J. Urol. 2003; 169: 145-8.
15. Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namiki M. Validity of sentinel lymph node concept for patients with prostate cancer. J. Urol. 2004; 171: 2268-71.
16. Meng MV, Carroll PR. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. J. Urol. 2000; 164: 1235-40.
17. El-Galley RE, Keane TE, Petros JA et al. Evaluation of staging lymphadenectomy in prostate cancer. Urology 1998; 52: 663-7.
18. Weingartner K, Ramaswamy A, Bittinger A, Gerharz EW, Voge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J. Urol. 1996; 156: 1969-73.
19. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol. Clin. North Am. 1997; 24: 395-406.
20. Petros JA, Catalona WJ. Lower incidence of unsuspected lymph node metastases in 521 consecutive patients with clinically localized prostate cancer. J. Urol. 1992; 147: 1574-5.
21. Cagiannos I, Karakiewicz P, Eastham JA et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J. Urol. 2003; 170: 1798-803.
22. Haese A, Epstein JI, Huland H, Partin AW. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer 2002; 95: 1016-21.
23. Naya Y, Babaian RJ. The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy. J. Urol. 2003; 170: 2306-10.
24. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-8.